“…In order to reduce the usage of intramammary antibiotic formulations, sustainable therapeutics are urgently needed (Barkema et al, 2006;McEwen and Fedorka-Cray, 2002). Probiotic products against udder diseases have been developed during the last decades and comprise bacteriocins for external application, such as lacticin 3147 or nisin as teat dips (Klostermann et al, 2010;Sears et al, 1992a), intramammarily applicated bacteriocins (Cao et al, 2007;Meaney et al, 2001;Pieterse et al, 2010;Ryan et al, 1998;Sears et al, 1992b;Twomey et al, 2000) and live probiotic microorganisms Frola et al, 2012). Some authors indicate that the probiotic strain should be obtained from the same ecological niche where the end product will be potentially applied, because autochthonous strains are better adapted to the specific environment and are more capable of epithelial colonization (Saarela et al, 2000).…”